National Oncology Centre.
Departments of Pediatrics.
Sultan Qaboos Univ Med J. 2021 Nov;21(4):578-584. doi: 10.18295/squmj.4.2021.032. Epub 2021 Nov 25.
A limited number of publications from the Middle East have focused on neuroblastoma, a common childhood malignancy. This study describes the clinical characteristics and survival outcome of Omani children with neuroblastoma treated at the National Oncology Centre, Oman, between 2010 and 2017.
From January 2010 to December 2017, data on Omani children aged less than 13 years with neuroblastoma were retrospectively collected. Survival data were statistically correlated with known prognostic factors, including age, stage of disease, MYCN profile and presence of metastasis.
A total of 56 Omani children were included. in this study. The male to female ratio was 1:1. The mean age at presentation was one year and 10 months. The two most common presenting complaints were body masses (48.2%) and constitutional symptoms (33.9%). Approximately, 54.5% were high risk, 35.7% were intermediate risk and 9.8% were low risk. High-risk neuroblastoma was mainly found in children older than one year (76.6%), with low risk mainly observed in children less than one year of age (80%). The overall survival of all groups combined was 74% ( <0.05); the event-free survival (EFS) was 67% ( <0.05). The overall survival rates over five years for the high-risk, intermediate-risk and low risk groups were 60%, 88% and 100%, respectively, and the EFS was 51%, 79% and 100%, respectively.
Omani children with neuroblastoma mainly presented with masses or constitutional symptoms and had an advanced disease at presentation which was associated with inferior survival. The survival outcomes were reasonably similar to published international data.
来自中东的少数出版物集中在神经母细胞瘤上,这是一种常见的儿童恶性肿瘤。本研究描述了 2010 年至 2017 年期间在阿曼国家肿瘤中心治疗的阿曼儿童神经母细胞瘤的临床特征和生存结果。
从 2010 年 1 月至 2017 年 12 月,回顾性收集了年龄小于 13 岁的阿曼儿童神经母细胞瘤的数据。生存数据与已知的预后因素(包括年龄、疾病分期、MYCN 谱和转移存在)进行了统计学相关分析。
本研究共纳入 56 名阿曼儿童。男女比例为 1:1。发病时的平均年龄为 1 岁 10 个月。最常见的两个临床表现是肿块(48.2%)和全身症状(33.9%)。约 54.5%为高危,35.7%为中危,9.8%为低危。高危神经母细胞瘤主要见于 1 岁以上的儿童(76.6%),而低危主要见于 1 岁以下的儿童(80%)。所有组别的总体生存率为 74%(<0.05);无事件生存率(EFS)为 67%(<0.05)。高危、中危和低危组的 5 年总生存率分别为 60%、88%和 100%,EFS 分别为 51%、79%和 100%。
阿曼儿童神经母细胞瘤主要表现为肿块或全身症状,且发病时疾病已处于晚期,与生存率降低相关。生存结果与已发表的国际数据相当相似。